A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: OPL-002

• Registration Number: NCT04451811
• Lead Sponsor: Oppilan Pharma Ltd

Brief Summary

This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-06-25
• Study First Submitted QC: 2020-06-25
• Study First Posted: 2020-06-30
• Status Verified: 2020-09
• Study Start: 2020-09-07
• Primary Completion: 2021-02-24
• Study Completion: 2021-02-24
• Last Update Submitted: 2021-05-26
• Last Update Posted: 2021-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Male or female (of non-childbearing potential only) between 18 and 55 years of age.

• Females must be of non-childbearing potential and must have undergone one of the following sterilization procedures, and have official documentation, at least 6 months prior to the first dose:

  1. hysteroscopic sterilization;
  2. bilateral tubal ligation or bilateral salpingectomy;
  3. hysterectomy;
  4. bilateral oophorectomy, or;
  5. be postmenopausal with amenorrhea for at least 1 year prior to the first dose and have FSH serum levels consistent with postmenopausal status as per investigator judgment.

• Male subjects must use reliable forms of contraception from screening to 30 days after the end of dosing.

• Good general health as determined by medical history, and by results of physical examination, vital signs, ECG, and clinical laboratory tests obtained within 28 days (4 weeks) prior to study drug administration.

Exclusion Criteria

• History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
• pressure and heart rate are outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic, heart rate 60-100 beats/min.
• 12-lead ECG with any abnormality judged by the Investigator to be clinically significant, QRS >= 110 milliseconds (msec), QT/QTcF interval of > 450 msec for men or >470 msec for women, or PR > 200 msec.
• Presence or history of any abnormality or illness, which in the opinion of the Investigator may affect absorption, distribution, metabolism or elimination of the study drug.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
OPL-002 SDD 20 mg	OPL-002	20 mg SDD formulation of OPL-002
OPL-002 5 mg Tablet	OPL-002	5 mg tablet formulation of OPL-002
OPL-002 20 mg Tablet	OPL-002	20 mg tablet formulation of OPL-002

Primary Outcome Measures

Name	Time	Method
AUC of OPL-002	0 to 48 hours

Secondary Outcome Measures

Name	Time	Method
Dose proportionality of 5 and 20 mg	0 to 48 hours
Absolute lymphocyte count	0 to 48 hours

Trial Locations

Locations (1)

Celerion; 🇬🇧 Belfast, Northern Ireland, United Kingdom